November 2, 2023 News by Lindsey Shapiro, PhD Stem cell transplant outperforms Lemtrada in MS treatment: Study A stem cell transplant was found to be better than Lemtrada (alemtuzumab) for lowering disease activity and slowing disability worsening in people with highly active relapsing forms of multiple sclerosis (MS), a small study in Lithuania showed. While both treatments were similarly effective in the first couple of…
September 28, 2023 News by Marisa Wexler, MS Lemtrada controlled RRMS disease activity more than a decade Over more than a decade of treatment with Lemtrada (alemtuzumab), relapse rates were low and about half of people with relapsing-remitting multiple sclerosis (RRMS) remained free of confirmed disability worsening, according to final results from the open-label TOPAZ clinical trial. “To our knowledge, this report represents the longest…
April 11, 2023 News by Margarida Maia, PhD Lemtrada aids cognitive skills, eases depression in real-world MS study One year of treatment with Lemtrada (alemtuzumab) significantly improved cognitive abilities, particularly with processing speed, and eased depression in people with relapsing forms of multiple sclerosis (MS), a small real-world study reported. Most of the 39 patients (92%) evaluated after that treatment year showed either stable or improved…
August 5, 2022 Columns by John Connor Pesky Leukocytes Dash My Hopes of Joining a Trial of Mavenclad for MS In December 2019, I was stopped in my tracks, or rather wheels, as I was about to have my third infusion of Ocrevus (ocrelizumab), the multiple sclerosis disease-modifying therapy (DMT) that Iād been taking every six months for the past year. My neurologist had decided just a few…
July 13, 2022 Columns by Beth Ullah Fighting Fire With Fire: The War Between Lemtrada and My MS āSo can you lift me up/ And turn these ashes into flames/ ‘Cause I have overcome/ More than words will ever say.ā ā Kate Voegele My relapsing-remitting multiple sclerosisĀ (RRMS) diagnosis stole my life from me. The reverberations of this unwelcome thunderbolt were astounding. Coming to terms with a…
June 1, 2022 Columns by Beth Ullah Tipping the Scale: When Todayās Choices Become Tomorrow’s Consequences Like watching a scale tip up and down, I’m constantly assessing how any choices I make could affect how I feel tomorrow, or even later today. Although my multiple sclerosis was as aggressive and unstable as a hurricane in my first few years with it, I’ve found a baseline…
May 27, 2022 News by Marisa Wexler, MS BBB Leakiness Decrease May Predict Effectiveness of Lemtrada Treatment Among multiple sclerosis (MS) patients starting on Lemtrada (alemtuzumab), an early decrease in the leakiness of the blood-brain barrier (BBB) is associated with a lower likelihood of disease activity after two years, according to a new study. The blood-brain barrier is a cellular divisor that regulates which substances…
May 23, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: DMTs and Symptoms, Aquatic Exercise, Infections āHiddenā Disabilities Fairly Common at RRMS Diagnosis, Study Finds This headline doesn’t report the full nature of this story. In addition to being “fairly common,” the research concludes that disease-modifying therapies (DMTs) have little effect on these so-called “hidden disabilities.”Ā I don’t agree with that conclusion. Most of…
April 13, 2022 Columns by Beth Ullah Pain and Positivity: My Experience With Plasmapheresis “‘Cause I would never break your heart/ I would only rearrange/ All the other working parts will stay in place.” ā Biffy Clyro, a Scottish rock band If youāve spent any time in a hospital, you know that it never gets completely dark. Thereās always a light flickering somewhere, a…
April 8, 2022 Columns by Ed Tobias Crossing the Lemtrada Finish Line I’m marking a big anniversary this month. It’s been four years since I finished the second round of treatment with Lemtrada (alemtuzumab), my final disease-modifying therapy (DMT). That means that, after about 60 monthly blood draws, I’m finished being stuck. Lemtrada is usually a two-phase series of injections, with…
April 6, 2022 Columns by Beth Ullah The Building Blocks of Becoming a Busy Bee āSerendipity. Look for something, find something else, and realize that what you’ve found is more suited to your needs than what you thought you were looking for.ā ā Lawrence Block When the world was thrown into lockdown at the dawn of COVID-19, I was already an old hand at functioning…
February 23, 2022 Columns by Beth Ullah The Furious Fire of Heat Sensitivity “In order to rise from its own ashes, a phoenix must first burn.ā ā Octavia E. Butler You know that feeling of waking up in a strange place, and it takes a second to remember where you are? Imagine that coupled with not being able to move from the neck…
January 10, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Lemtrada, Music and White Matter, Diagnosing MS AB Science OKād to Start Masitinib Phase 3 Trial for Progressive MS Many of us with multiple sclerosis (MS) have been waiting for another treatment for progressive forms of MS. I hope this brings us another step closer to one. Masitinib is an oral medication that works by blocking…
January 5, 2022 News by Yedida Y Bogachkov PhD Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, āAutoimmunity and long-term safety and efficacy…
December 3, 2021 Columns by Ed Tobias My Lemtrada Treatment, 5 Years Later It was five years ago, Dec. 5, 2016, that I scootered into the office of Dr. Heidi Crayton, my neurologist, and plopped into a soft, brown leather recliner. Day 1 of Round 1 of my Lemtrada (alemtuzumab)Ā infusions was about to begin. I’d prepped for this day: two days…
November 12, 2021 Columns by Ed Tobias I’m Sleeping Better These Days, but Why? I had a great night’s sleep the other night. I fell asleep quickly and slept straight through the night for nearly seven hours. When I got up in the morning, I felt refreshed, which is exceedingly rare these days. Plus, it even happened a few more times in the past…
September 22, 2021 Columns by Beth Ullah Overcoming the Loneliness and Isolation of Aggressive MS āHurricane MS,ā which is how I refer to the aggressive nature of my MS progression, happened quickly and mercilessly. I am aware that my case is particularly unusual, given how aggressive its onset was. This is one of the reasons I feel a sense of purpose in sharing my story…
August 16, 2021 News by Marisa Wexler, MS Lemtrada Does Not Lead to Brain Bleeds, Small Belgian Study Says Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to bleeding in the brain of multiple sclerosis (MS) patients, according to a small Belgian study. The findings contrast with previous studies showing an increase in blood pressure, stroke, and…
June 28, 2021 News by Marisa Wexler, MS Early Use of High-efficacy DMTs Favor Lesser Disability Over Time Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…
April 23, 2021 Columns by Ed Tobias Let’s Treat Older MS Patients With More Respect As comic Rodney Dangerfield might have said, older people with MS “just don’t get no respect.” By older, I mean those of us who are 55 and up. By respect, I mean from researchers and some neurologists. So, as I approach my 73rd birthday, I have to tip my cap…
January 12, 2021 News by Diana Campelo Delgado Lemtrada May Slow MS Disease Progression, Long-term Study Suggests LemtradaĀ (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results showed that patients converting to SPMS ā in which a personās disability gets steadily worse ā were older,…
December 30, 2020 Columns by Ed Tobias Will Reduced Treatment Time Keep Ocrevus Competitive? One of the key considerations when choosing a disease-modifying therapy (DMT) is how much it will disrupt your life. It’s one of several factors that need to be evaluated. Unlike shots and pills, infusion treatments can require a significant amount of time. That’s why the U.S. Federal Drug Administration’s December…
November 10, 2020 News by Marta Figueiredo, PhD Stem Cell Transplant More Effective Than Lemtrada in Treating RRMS, Study Suggests An autologous hematopoietic stem cell transplantĀ (AHSCT) is more effective than LemtradaĀ (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosisĀ (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…
February 17, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: Report on Ocrevus Use, Cognitive Decline in MS, Gold Nanocrystals and Remyelination Study Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS Ocrevus (ocrelizumab) bolted out of the starting gate after it was approved for use in the U.S. about three years ago. However, though its use by people with relapsing forms of multiple sclerosis continues…
February 14, 2020 Columns by John Connor And the Biofilm Goes to … The medical profession must be sick and tired of patients diagnosing themselves via the wonders of the internet. But as a patient who’s sick and tired, you eventually have to. Medicine is full of orthodoxies that are incredibly hard to shake. When you find yourself at the edge of these…
January 17, 2020 Columns by Ed Tobias Stem Cells Versus DMTs: MS Treatments Go Head to Head People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and it’s enrolling people with MSĀ at several centers in the United States and…
January 6, 2020 News by Patricia Inacio, PhD Brain Regeneration Impaired in Progressive MS, Unaffected By DMTs, Study Reports Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports. The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels…
November 5, 2019 News by Ana Pena PhD EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals with ICUs Seven months after starting a safety review of Lemtrada (alemtuzumab), the Pharmacovigilance Risk…
October 11, 2019 News by Ana Pena PhD Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports Prescriptions of two multiple sclerosisĀ (MS) treatments ā Ā Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab) ā have been rising in Europe over the past six months, bolstered by greater market access and compassionate use programs, according to a survey of 250 EU neurologists run…
August 28, 2019 News by Jose Marques Lopes, PhD Mavenclad Cost-Effective Treatment for At-risk RRMS Patients Compared to Other DMTs, Dutch Study Finds Treating at-riskĀ relapsing-remitting multiple sclerosis (RRMS) patients is most cost-effective withĀ MavencladĀ (cladribine) tablets when compared to Gilenya (fingolimod), Lemtrada (alemtuzumab) or Tysabri (natalizumab),Ā according to a study in Dutch patients. The study, āCost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in…